Vital

Peptides

GHK-Cu Injection Dosage: Evidence, FDA Status, Unit Math

There is no approved GHK-Cu injection dosage. Learn what the topical and injected evidence shows, where the FDA stands in 2026, how units work for a 50 mg vial, and which side effects need care.

Last reviewed

The Vital angle

Vital's reconstitution calculator takes the peptide mass in mg or mcg and the water volume, and shows the concentration in mg/mL and mcg/mL. For an amount your prescriber gives you, it shows the draw in U-100 units and mL and the doses per vial. Each dose log keeps the site, symptoms with a severity, and notes.

GHK-Cu injection dosage: the short answer

There is no approved GHK-Cu injection dosage. GHK-Cu is not an FDA-approved drug for any use, and no published human trial has tested it as an injection. The milligram numbers that rank in search for "GHK-Cu injection dosage" come from sellers, clinics and community forums. They do not come from a drug label or a controlled trial.

The FDA's own list says the point plainly. Its 503A nominations list, updated May 14, 2026, keeps GHK-Cu under evaluation only "except for injectable routes of administration." This guide explains what is known about topical and injected GHK-Cu, how the unit math on a vial works with hypothetical numbers, and which side effects need medical care. It does not recommend a dose, a schedule or a cycle.

What GHK-Cu is

GHK is a three-amino-acid peptide (glycine, histidine, lysine) that is present in human plasma, saliva and urine. It binds copper, and the copper complex is called GHK-Cu. Reviews describe GHK effects on collagen, wound repair and skin in lab and animal work, and note that GHK levels in plasma fall with age.

Two points matter when you read those reviews:

  • The best-known reviews of GHK come from authors at a company that sells copper peptide skin products.
  • The human results in those reviews are mostly for cosmetic creams and serums on the skin, not for injection.

Topical vs injected evidence

The evidence for the two routes is very different.

Question Topical GHK-Cu Injected GHK-Cu
Used in human studies Yes, mostly small cosmetic studies No published human trial found
Registered human trials (ClinicalTrials.gov, checked November 2026) Gel and serum studies None for injection
FDA 503A status Category 1, under evaluation Excluded from category 1
Human dose data Product concentrations in creams None

A search of ClinicalTrials.gov in November 2026 found a study of a topical GHK-Cu gel for skin wounds, a study of a topical peptide serum, and a skin patch study that measured GHK levels in the blood. None tested a GHK-Cu injection. A result from a cream on the face does not tell you what the same peptide does when it is injected under the skin and reaches the blood.

FDA status for injectable GHK-Cu

The FDA keeps a page on bulk drug substances that may present significant safety risks in compounding. On the version current as of April 22, 2026, GHK-Cu for injectable routes is in the table of withdrawn nominations. The FDA notes that compounded injectable versions may pose a risk of immunogenicity because of aggregation and peptide-related impurities, and that limited human data are available.

  • On May 14, 2026, the FDA put GHK-Cu back in category 1 for non-injectable routes only.
  • The FDA plans to consult its compounding advisory committee about GHK-Cu before the end of February 2027.
  • The July 2026 advisory committee vote on six other peptides did not include GHK-Cu.

Category 1 is not an approval. It means a substance is under evaluation for compounding. Products labeled "for research use only" are not made or checked as drugs for people. Check the FDA pages for the current position, because they change.

GHK-Cu 50 mg vial: how the units work

Because no approved human dose exists, the example below uses hypothetical round numbers only. It shows the arithmetic. It is not a dose and not a suggestion.

  1. Assume a hypothetical vial holds 50 mg of GHK-Cu powder.
  2. Assume it is mixed with 5 mL of bacteriostatic water. The concentration is 50 ÷ 5 = 10 mg per mL.
  3. On a U-100 insulin syringe, 100 units fill 1 mL, so 1 unit is 0.01 mL.
  4. Each unit then holds 10 mg × 0.01 = 0.1 mg.
Water added to a hypothetical 50 mg vial Concentration Amount in 10 units (0.1 mL)
2 mL 25 mg/mL 2.5 mg
2.5 mL 20 mg/mL 2 mg
5 mL 10 mg/mL 1 mg

The same mark on the syringe holds 2.5 times as much GHK-Cu with 2 mL of water as with 5 mL. To find how many draws a vial holds, divide the vial mass by the mass in one draw. Confirm every draw with your prescriber or pharmacist, in mL as well as units, before you inject.

You can check your own numbers in the free peptide calculator. For mixing, see how to reconstitute peptides with BAC water. For the syringe scale, see how to read an insulin syringe for peptides, and for vial counts, see how many doses are in a vial.

How much copper is in GHK-Cu

GHK-Cu is a copper complex, so every milligram carries copper. Based on the molecular weights, copper is roughly 16 percent of the mass of GHK-Cu. In the hypothetical 1 mg draw above, that is about 0.16 mg of copper.

No published study has measured blood copper, ceruloplasmin or zinc in people who inject GHK-Cu. There is no injected safety limit for copper from this source. Diet limits for copper apply to food, which the gut absorbs and the liver controls, so they do not convert to an injected amount. People with Wilson disease or another copper disorder have a specific reason to talk to a clinician first.

GHK-Cu injection side effects and the sting

Because no controlled human injection trial exists, there is no measured side effect rate for injected GHK-Cu. What is available comes from user reports and general injection risks.

  • Sting or burn at the site. This is a common complaint in user reports. No published study has measured it or its cause.
  • Redness, swelling, bruising or a hard lump at the injection site.
  • Infection from a non-sterile vial or technique.
  • Immune reactions, which the FDA lists as a possible risk for compounded injectable GHK-Cu.

Mixed GHK-Cu is blue because of the copper, so the color alone does not show a problem. Cloudy liquid or particles do. A sting is not a sign that a vial is working or failing. If a site stays painful, grows or spreads, stop and get care. Mild site reactions are covered in peptide injection site reactions, and site rotation is in the injection site rotation chart.

How Vital helps you track GHK-Cu

Vital has a reconstitution calculator. You enter the peptide mass in mg or mcg and the water volume, and Vital shows the concentration in mg/mL and mcg/mL. When you enter an amount that your prescriber gave you, it shows the draw on a U-100 syringe in units and mL, plus how many doses the vial holds.

Each dose log keeps the injection site, any symptoms with a severity, and notes. That record helps if a site reaction starts and a clinician asks when it began. Vital is a tracking tool. It does not suggest a dose, and it does not say whether GHK-Cu is right for you. If you use GHK-Cu inside a blend, see the Glow peptide blend guide.

Warning signs that need care

Get medical care right away for:

  • A hot, red, spreading or very painful injection site, pus, or a fever.
  • A lump that grows or does not go away.
  • Nausea, vomiting, belly pain, dark urine or yellow skin or eyes, which can be signs of a liver or copper problem.

Get emergency care for swelling of the face, lips, tongue or throat, hives over the body, or trouble breathing. Tell every clinician you see that you inject GHK-Cu, and bring the vial label and your log.


Vital is independent and not affiliated with any peptide seller, compounder or drug maker.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Injected GHK-Cu

    Not an FDA-approved drug. The FDA's category 1 entry excludes injectable routes, and the FDA notes a possible immunogenicity risk and limited human data for compounded injectable versions.

  • Copper load

    Copper is roughly 16 percent of the mass of GHK-Cu. No study has measured blood copper in people who inject it, and no injected safety limit exists.

  • Topical results used for injection claims

    Most human GHK-Cu studies test creams, gels or serums on the skin. They do not show what an injection does.

  • Research use only vials

    Products labeled for research use only are not made or checked as drugs for people, so identity, sterility and labeled mass are not assured.

  • Water volume left off the log

    The same syringe mark holds 2.5 times as much GHK-Cu with 2 mL of water as with 5 mL, so a log without the volume cannot be checked.

Frequently asked questions

  • No approved dose exists. GHK-Cu is not an FDA-approved drug, and no published human trial has tested it as an injection. Online numbers come from sellers and forums. Ask a licensed prescriber before you use it.

  • It depends on the water. As math only, 50 mg in 5 mL is 10 mg per mL, so 10 units on a U-100 syringe (0.1 mL) hold 1 mg. With 2.5 mL, the same 10 units hold 2 mg. Confirm any draw with your pharmacist.

  • A sting is a common complaint in user reports, but no published study has measured it or its cause. If a site stays painful, grows, gets hot or spreads, stop and get medical care.

  • Yes. Most human studies of GHK-Cu test creams, gels or serums on the skin. ClinicalTrials.gov listed no injection trials when checked in November 2026.

  • No. In May 2026 the FDA put GHK-Cu back in category 1 for non-injectable routes only. The FDA plans to consult its compounding advisory committee about GHK-Cu before the end of February 2027.

  • No controlled trial has measured them. Reports describe sting, redness, swelling and lumps at the site. The FDA lists a possible immune reaction risk. Get emergency care for face or throat swelling or trouble breathing.

Sources

  1. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act · U.S. Food and Drug Administration
  2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  3. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · International Journal of Molecular Sciences, via PubMed
  4. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · BioMed Research International, via PubMed
  5. Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586) · ClinicalTrials.gov, U.S. National Library of Medicine

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.